The Lipoprotein(a) Revolution: How RNA Therapies Are Rewriting Cardiovascular Prevention for the One in Five Born With Hidden Heart Risk

For six decades, cardiology has lived with a strange and uncomfortable truth. A single inherited blood particle, identified in Norway in 1963 by Kare Berg, doubles or triples the lifetime risk of heart attack, stroke, and aortic valve disease in roughly one in five adults worldwide. The medical community has known about it since the Beatles released their first album. Yet until very recently, doctors who measured it had nothing to offer the patients who tested high.

Presented By Our Partners

That is now changing. Three Phase 3 clinical trials, running in parallel across more than 50 countries, are evaluating RNA based therapies that reduce blood levels of this particle by 80 to 98 percent with a single subcutaneous injection given as infrequently as twice a year. The drugs, olpasiran from Amgen, pelacarsen from Novartis, and lepodisiran from Eli Lilly, represent the first true pharmacology ever directed at lipoprotein(a). Top line outcome data from the first of these trials is expected in 2026 and 2027. Cardiology has been waiting for this moment since the Kennedy administration.

This is the story of what lipoprotein(a) actually is, why generations of statins and PCSK9 inhibitors cannot touch it, why three of the largest pharmaceutical companies in the world are racing to be first to market, and what current science says you should do today if your level is high.

What Lipoprotein(a) Is and Why It Is Different

Lipoprotein(a), almost always abbreviated as Lp(a) and pronounced "L P little a," looks at first glance like an oddball cousin of LDL cholesterol. The core particle is essentially identical: a sphere of cholesterol and triglycerides wrapped in a protein called apolipoprotein B. What makes Lp(a) different, and dangerous, is a second protein bolted to the apoB by a single disulfide bond. That protein is called apolipoprotein(a), or apo(a), and it has no obvious physiological purpose. It looks evolutionarily like a hijacked, mutated copy of the clotting protein plasminogen.

This structural quirk turns out to matter enormously. The apo(a) tail makes the particle proatherogenic, meaning it drives plaque formation; prothrombotic, meaning it promotes clotting; and proinflammatory, meaning it concentrates oxidized phospholipids that inflame the artery wall. A 2008 paper by Bergmark and colleagues in the Journal of Lipid Research showed that Lp(a) is the dominant carrier of oxidized phospholipids in human blood. A 2014 Mendelian randomization study by Kamstrup and Nordestgaard in JAMA, drawing on the Copenhagen General Population Study, demonstrated that the relationship between Lp(a) levels and heart attack risk is causal, not merely correlated. Genes that randomly assign people to higher Lp(a) from birth also randomly assign them to higher cardiovascular event rates decades later.

The most consequential fact about Lp(a) is that levels are roughly 90 percent genetic. Diet, exercise, and statins barely move it. A person born with high Lp(a) is, in effect, walking into adulthood with a clock already started. Carriers of certain LPA gene variants have lifetime odds of myocardial infarction comparable to having had a previous heart attack themselves, even if their LDL cholesterol is well controlled and they have no other risk factors.

The Scale of the Problem

The European Atherosclerosis Society 2022 consensus statement and the American College of Cardiology 2024 pathway document both estimate that roughly 20 percent of the global population, around 1.4 billion people, have Lp(a) levels above the 50 mg/dL or 125 nmol/L threshold associated with meaningfully elevated cardiovascular risk. People of African ancestry tend to run higher than people of European ancestry, who in turn run higher than people of East Asian ancestry, though there is enormous variation within every group.

Despite this prevalence, fewer than 1 percent of adults in the United States have ever had their Lp(a) measured. The Cleveland Clinic, the Mayo Clinic, and several large integrated health systems have begun universal one time Lp(a) screening, on the logic that the level is essentially fixed for life and only needs to be measured once. The European Society of Cardiology 2019 dyslipidemia guidelines and the National Lipid Association 2024 scientific statement both now recommend a one time measurement in every adult. Most physicians, including most cardiologists outside academic centers, have not yet adopted the practice.

This gap matters because Lp(a) elevation is a strong, independent, and frequently silent driver of three of the most serious vascular events in adult medicine. The 2022 European consensus paper estimated that 30 percent of premature heart attacks under age 55 are attributable to elevated Lp(a). The Copenhagen City Heart Study showed that Lp(a) is the single strongest blood lipid predictor of calcific aortic valve stenosis, the disease that puts hundreds of thousands of patients into the cardiac surgery suite each year for valve replacement. Recent work from the Atherosclerosis Risk in Communities cohort and from the UK Biobank links Lp(a) to ischemic stroke, peripheral artery disease, and even certain forms of venous thromboembolism.

Why Statins Do Not Help

Statins, the most prescribed class of cardiovascular drugs in human history, have transformed the prognosis of patients with high LDL cholesterol. They do essentially nothing for Lp(a). Several pooled analyses, including a 2020 meta-analysis in the European Heart Journal led by de Boer and colleagues, have actually shown that statin therapy may modestly raise Lp(a) by 8 to 24 percent in some patients, though the absolute effect is small and the residual cardiovascular benefit of statins remains intact.

PCSK9 inhibitors, the injectable LDL lowering drugs evolocumab and alirocumab, reduce Lp(a) by 20 to 30 percent. That is a real effect, and the FOURIER and ODYSSEY OUTCOMES trials suggest the Lp(a) reduction contributes a small fraction of the cardiovascular benefit. But a 25 percent reduction from an extremely elevated baseline still leaves the patient in the high risk zone. Niacin can reduce Lp(a) by 20 to 30 percent as well, but the AIM-HIGH and HPS2-THRIVE outcome trials showed no clinical benefit and substantial side effects, so it has fallen out of favor.

Lipoprotein apheresis, a mechanical filtration of the blood somewhat like dialysis, can drop Lp(a) by 60 to 75 percent acutely but the level rebounds within two weeks. It is approved in Germany, reimbursed in a narrow set of US indications, and is used in fewer than 1,000 patients in the entire United States.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

For decades, that was the entire pharmacopoeia. The field needed a drug aimed directly at the LPA gene.

The RNA Therapy Era Arrives

The breakthrough came from the same antisense and small interfering RNA chemistry that produced inclisiran for LDL and patisiran for hereditary ATTR amyloidosis. In 2020, Ionis Pharmaceuticals and Novartis published a Phase 2 trial of pelacarsen, an antisense oligonucleotide that binds LPA messenger RNA in the liver and prevents apo(a) protein from being made. The trial, led by Sotirios Tsimikas at UC San Diego and published in the New England Journal of Medicine, showed Lp(a) reductions of up to 80 percent with monthly subcutaneous injection.

Amgen followed with olpasiran, a small interfering RNA conjugated to a GalNAc sugar that targets it to hepatocytes. The OCEAN(a) DOSE Phase 2 trial, published in the New England Journal of Medicine in 2022 by Michelle O’Donoghue and colleagues at Brigham and Women’s Hospital, showed Lp(a) reductions of more than 95 percent at 36 weeks with dosing every 12 weeks. Eli Lilly’s lepodisiran, another siRNA, showed reductions of up to 98 percent in a Phase 1 trial published in JAMA in 2023, with a duration of effect long enough to support twice yearly dosing.

The Phase 3 cardiovascular outcomes trials are now the only data the field is waiting for.

HORIZON, the Phase 3 trial of pelacarsen, randomized roughly 8,300 patients with established cardiovascular disease and Lp(a) at or above 70 mg/dL to monthly pelacarsen or placebo. The trial completed enrollment in 2024. Top line results are expected in 2026.

OCEAN(a) Outcomes, the Phase 3 trial of olpasiran, enrolled more than 6,000 patients with prior atherosclerotic cardiovascular disease and elevated Lp(a). Read out is anticipated in 2027.

ACCLAIM-Lp(a), the Phase 3 outcomes trial of lepodisiran, enrolled approximately 12,500 patients and is the largest of the three. Twice yearly dosing makes it the most operationally interesting if it succeeds.

A fourth program, muvalaplin from Eli Lilly, takes a fundamentally different approach. It is a small molecule oral pill that physically blocks the assembly of apo(a) onto apoB, preventing the Lp(a) particle from forming in the first place. A Phase 2 trial in JAMA in 2024 by Stephen Nicholls and colleagues at Monash University showed Lp(a) reductions of up to 85 percent with once daily oral dosing. Lilly has not yet committed to a cardiovascular outcomes trial for muvalaplin, but the pill route would dramatically broaden the addressable population if the Phase 3 outcomes data for the injectables turns out to be positive.

What the Outcomes Trials Need to Show

It is one thing to lower a biomarker by 90 percent. It is another to show that doing so prevents heart attacks and strokes. The history of cardiology is full of biomarkers that turned out to be bystanders rather than causes, or causes whose modification did not deliver clinical benefit.

The case for Lp(a) being causal rather than correlative is unusually strong. Mendelian randomization studies, in which inherited genetic variants are used as natural randomized exposures, consistently show that lower lifetime Lp(a) levels predict lower cardiovascular event rates in a dose dependent way. A 2018 paper by Burgess and colleagues in JAMA Cardiology calculated that a 100 mg/dL absolute reduction in Lp(a) would be expected to deliver roughly the same relative cardiovascular risk reduction as a 38 mg/dL reduction in LDL cholesterol, which is approximately what a moderate intensity statin produces.

The Phase 3 trials are designed around that calculation. They are powered to detect a relative risk reduction in the range of 15 to 25 percent in major adverse cardiovascular events over three to five years of follow up. If they hit those endpoints, the drugs will represent the first new class of cardiovascular outcome modifying lipid therapy since PCSK9 inhibitors a decade ago.

If they miss, the field will face a harder conversation about whether Lp(a) is, in fact, a causal driver in the time horizon of an adult clinical trial, or whether lifelong elevation produces damage that cannot be reversed in middle age.

The Diagnostic Bottleneck

Even if the trials succeed, the largest barrier to clinical impact will not be the drug. It will be the test. Lp(a) measurement is offered by most major commercial laboratories and is inexpensive, often under 20 dollars on a cash pay basis. But the test is rarely ordered. The standard lipid panel that every American adult gets at an annual physical does not include it.

A 2023 paper in Circulation by Bhatia and colleagues at Mass General Brigham showed that among 2.4 million adults in a large integrated health system, only 0.6 percent had ever had an Lp(a) measured. Among patients with documented atherosclerotic cardiovascular disease, the rate was still under 5 percent.

This is the practical implication of the Phase 3 trials succeeding. If even one of the three drugs is approved, the cardiology community will need to make universal one time Lp(a) screening a clinical standard. The infrastructure for doing this already exists. The reimbursement, education, and electronic health record nudges do not.

What This Means For You

If you are an adult who has never had Lp(a) measured, ask your physician to add it to your next blood draw. The test costs little, you only need it done once, and it provides information no other lipid measurement can replace. A value below 30 mg/dL or 75 nmol/L is reassuring. A value above 50 mg/dL or 125 nmol/L meaningfully raises your cardiovascular and aortic valve risk and should prompt a conversation with a lipid specialist or preventive cardiologist.

If your Lp(a) is high, the current standard of care is to manage every other modifiable risk factor more aggressively. LDL cholesterol should be driven as low as your clinician deems safe, often below 70 mg/dL and in some cases below 55 mg/dL, using statins, ezetimibe, and a PCSK9 inhibitor or bempedoic acid if needed. Blood pressure, blood glucose, smoking status, and inflammatory markers all matter more in a high Lp(a) context, not less. The 2024 American College of Cardiology consensus pathway recommends considering low dose aspirin in primary prevention for patients with high Lp(a) and otherwise elevated atherosclerotic risk, a recommendation that does not apply to the general population.

Family members of patients with very high Lp(a) levels should also be screened. The trait is autosomal codominant, meaning roughly half of first degree relatives will share the elevation. Pediatric screening is increasingly common in families with strong premature cardiovascular history.

If you are below age 50 with an Lp(a) above 100 mg/dL, especially with a family history of premature heart attack, talk to your cardiologist about whether you are a candidate for one of the ongoing Phase 3 trials. Several of the programs are still recruiting, and trial participation is one of the few ways to access these drugs before approval.

For the broader healthcare ecosystem, the Lp(a) story is a case study in how slowly a known disease driver can move through the gap between knowing and treating. Berg identified the particle in 1963. The first outcomes trials of a drug aimed at lowering it will read out in 2026. The 63 years in between are the kind of timeline that the precision medicine and longevity science movements are explicitly trying to compress.

For the field of cardiology, the rest of the decade will be defined by whether the Lp(a) drugs work in the trials, whether health systems institute universal screening, and whether the next generation of lipid management moves from a single LDL number to a full inherited risk profile that includes Lp(a), apoB, polygenic risk scores, and high sensitivity inflammatory markers. That shift is already underway in academic preventive cardiology. The Phase 3 readouts of the next 18 months will decide how quickly it reaches everyone else.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.